Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

Kim Fox, Ian Ford, P Gabriel Steg, Michal Tendera, Roberto Ferrari, BEAUTIFUL Investigators, Gordon Murray (Member of Group Organisation), Christopher Weir (Member of Group Organisation)

Research output: Contribution to journalArticlepeer-review

Abstract

Ivabradine specifically inhibits the I(f) current in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function. We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease and left-ventricular systolic dysfunction.
Original languageEnglish
Pages (from-to)807-16
Number of pages10
JournalThe Lancet
Volume372
Issue number9641
DOIs
Publication statusPublished - 2008

Fingerprint

Dive into the research topics of 'Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this